Daily Endocrinology Research Analysis
Analyzed 72 papers and selected 3 impactful papers.
Summary
Non-invasive liver stiffness by transient elastography matched biopsy for prognosticating liver-related events in MASLD, supporting its use as a surrogate endpoint. Oral small-molecule GLP-1 receptor agonists (danuglipron, orforglipron) improved glycemia and weight but increased GI adverse events. A CADD-engineered peptide degrader (Cadd4) targeted intracellular PCSK9, lowering LDL-C in vivo and outperforming a clinical-stage comparator, highlighting a novel lipid-lowering modality.
Research Themes
- Non-invasive prognostic tools in metabolic liver disease
- Oral small-molecule GLP-1 receptor agonists for diabetes and obesity
- Targeted protein degradation for lipid lowering (PCSK9)
Selected Articles
1. Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease.
In 3,532 MASLD patients with both biopsy and VCTE, liver stiffness predicted liver-related events as accurately as histology over a median 56.6 months. Five-year AUROC, integrated AUROC, precision-recall, and Brier scores were comparable, supporting LSM as a non-invasive surrogate endpoint for trials.
Impact: This is the largest head-to-head comparison showing non-invasive LSM matches histology for prognosis, potentially transforming endpoints in MASLD trials and reducing reliance on biopsy.
Clinical Implications: LSM by VCTE can be used to stratify risk and monitor MASLD prognosis without biopsy, and may serve as an acceptable surrogate endpoint in clinical trials, streamlining patient management and trial design.
Key Findings
- In 3,532 MASLD patients, median follow-up 56.6 months, 3.6% developed liver-related events.
- Five-year AUROC for predicting LREs was virtually identical for LSM versus histology (0.870 vs 0.869).
- Integrated AUROC, precision-recall, and 5-year Brier scores were similar, with no significant discrimination improvement between methods.
- Findings were consistent across outcomes, time points, and sensitivity analyses.
Methodological Strengths
- Large multicenter cohort with both VCTE and liver biopsy at baseline
- Robust prognostic metrics (AUROC, iAUC, precision-recall, Brier scores) with sensitivity analyses
Limitations
- Observational design may be prone to selection and residual confounding
- Low event rate (3.6%) may limit power for subgroup analyses
Future Directions: Prospective validation of LSM as a regulatory-acceptable surrogate endpoint, evaluation of serial LSM changes, and external validation in diverse populations.
BACKGROUND AIMS: Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) correlates well with liver-related events (LREs), but previous head-to-head comparisons with liver histology were limited by small sample size. This study aimed to compare the prognostic performance of LSM and histology for predicting LREs in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). APPROACH RESULTS: We analyzed data from 3,532 MASLD patients (mean age 51.9 years, 57.3% male) in the multicenter VCTE-Prognosis cohort, all having undergone both LSM and liver biopsy. The primary outcome was LREs, defined as hepatic decompensation, liver transplantation, or liver-related death. Secondary outcomes included HCC and decompensation analyzed separately. Median baseline LSM was 8.8 kPa; 33.5% had F3-F4 fibrosis. Over a median follow-up of 56.6 months, 126 patients (3.6%) developed LREs (123 decompensation). LSM and histology demonstrated similar prognostic performance for LREs, with comparable 5-year area under the receiver operating characteristic curve (AUROC) values (0.870 vs. 0.869), integrated AUROCs (0.878 vs. 0.852), and integrated precision-recall curves (0.137 vs. 0.0.68). The 5-year integrated Brier scores were also similar (1.389% vs. 1.391%), and the integrated discrimination improvement index showed no significant difference. Similar results were found across all the outcomes, time-points, and sensitivity analyses. CONCLUSIONS: In this large MASLD cohort, LSM by VCTE showed comparable prognostic accuracy to histology. As a non-invasive tool, LSM may serve as an alternative surrogate endpoint in clinical trials.
2. The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
Across eight RCTs (n=1,454), danuglipron and orforglipron significantly lowered HbA1c, fasting glucose, and body weight; orforglipron also reduced BMI. Both agents increased treatment-related and GI adverse events, underscoring the need for longer-term safety and tolerability data.
Impact: Demonstrates clinically meaningful glycemic and weight benefits of first-in-class oral small-molecule GLP-1 RAs, a potential paradigm shift for patients preferring non-injectable incretin therapy.
Clinical Implications: Oral GLP-1 RAs may expand access and adherence for incretin therapy, offering HbA1c and weight reductions; clinicians should monitor GI tolerability and await long-term cardiovascular and safety outcomes.
Key Findings
- Danuglipron reduced HbA1c by −0.90%, fasting plasma glucose by −24.66 mg/dL, and body weight by −2.17 kg.
- Orforglipron reduced HbA1c by −1.02%, fasting plasma glucose by −26.91 mg/dL, body weight by −6.28 kg, and BMI by −2.64 kg/m2.
- Both agents were associated with higher rates of treatment-related and gastrointestinal adverse events.
Methodological Strengths
- Meta-analysis of randomized controlled trials with low risk of bias
- Consistent effects across glycemic and anthropometric endpoints
Limitations
- Heterogeneity in dosing regimens and trial durations
- Limited long-term safety and cardiovascular outcome data
Future Directions: Head-to-head trials versus injectable GLP-1 RAs, longer-term cardiovascular outcome trials, and optimization of dosing to improve GI tolerability.
OBJECTIVE: This study assesses the efficacy and safety of the novel oral small molecule glucagon-like peptide-1 receptor agonists (GLP-1 RAs) danuglipron and orforglipron in the treatment of type 2 diabetes (T2DM) and obesity through systematic review and meta-analysis. METHODS: Electronic databases (PubMed, Web of Science, Cochrane Library and Embase) were systematically searched up to 20 May 2025 to include randomised controlled trials evaluating danuglipron/orforglipron in patients with T2DM and/or obesity. Changes in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), fasting plasma insulin (FPI), weight and body mass index (BMI) compared with baseline post-treatment were evaluated using random-/fixed-effects models, alongside safety outcomes. RESULTS: Eight studies with low bias risk involving 1,454 participants were analysed. Meta-analysis results demonstrated that danuglipron significantly decreased HbA1c (mean difference [MD]: -0.90; 95% CI: -1.06, -0.74), FPG (MD: -24.66; 95% CI: -30.45, -18.86) and weight (MD: -2.17; 95% CI: -3.10, -1.23) and improved FPI (MD: 2.94; 95% CI: 1.50, 4.38). Orforglipron also showed significant positive effects on HbA1c (MD: -1.02; 95% CI: -1.18, -0.86), FPG (MD: -26.91; 95% CI: -31.05, -22.78), weight (MD: -6.28; 95% CI: -8.45, -4.11) and BMI (MD: -2.64; 95% CI: -3.38, -1.89). However, both danuglipron and orforglipron were associated with the occurrence of treatment-related adverse events and gastrointestinal adverse events (AEs). CONCLUSION: The oral GLP-1 RAs danuglipron and orforglipron are capable of improving blood glucose levels and reducing weight; however, they also pose an increased risk of gastrointestinal AEs. Further longitudinal studies are warranted to gain a deeper understanding of their efficacy, safety and tolerability.
3. CADD-engineered peptide protacs efficiently target PCSK9 for hypercholesterolemia in vivo.
A CADD-designed peptide PROTAC (Cadd4) achieved intracellular PCSK9 degradation, increased LDLR, and reduced LDL-C by 29% in hypercholesterolemic mice, with liver-specific accumulation and no systemic toxicity. Ex vivo human liver data and superiority to AZD0780 suggest translational promise.
Impact: Introduces a first-in-class peptide degrader for intracellular PCSK9, overcoming limitations of antibody therapies and expanding targeted protein degradation into lipid disorders.
Clinical Implications: If confirmed in humans, peptide degraders of PCSK9 could provide durable LDL-C lowering with liver targeting and potentially improved access or adherence compared with injections.
Key Findings
- Cadd4 reduced hepatic PCSK9 by 38% and increased LDLR expression in vitro and in vivo.
- In HFD mice, total cholesterol decreased by 25% and LDL-C by 29% with liver-specific accumulation and no systemic toxicity.
- Ex vivo human liver tissues showed effective PCSK9 degradation and LDLR restoration; Cadd4 outperformed AZD0780 in lipid lowering and duration.
Methodological Strengths
- Rational CADD-driven design with validation across in vitro, in vivo, and human ex vivo systems
- Biodistribution and toxicity profiling demonstrating liver specificity and safety
Limitations
- Preclinical models; human pharmacokinetics, dosing, and long-term safety unknown
- Sample sizes and replication across species not detailed in abstract
Future Directions: Advance to large-animal studies and first-in-human trials to define dosing, safety, and durability; explore combination with statins or ezetimibe and effects on Lp(a).
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of low-density lipoprotein receptors (LDLR), leading to elevated plasma LDL cholesterol (LDL-C) and increased risk of hypercholesterolemia. Current therapeutic approaches, such as monoclonal antibodies and gene-editing tools, face significant challenges including high cost, safety issues, and limited ability to target intracellular PCSK9. METHODS: Using computer-aided drug design (CADD), we developed Cadd4, a novel peptide-based degrader targeting PCSK9. Molecular docking was employed to identify a high-affinity peptide sequence, which was then validated through in vitro studies using LX-2 cells and in vivo experiments in high-fat diet (HFD)-induced hypercholesterolemic mice. Biodistribution and toxicity assessments were performed to evaluate tissue specificity and safety. Human liver tissue experiments were conducted to assess translational efficacy. RESULTS: Cadd4 exhibited efficient intracellular uptake and significantly reduced PCSK9 levels, resulting in upregulated LDLR expression. In HFD-fed mice, hepatic PCSK9 was decreased by 38 %, accompanied by a 25 % reduction in total cholesterol and a 29 % reduction in LDL-C. Biodistribution analysis revealed liver-specific accumulation with no signs of systemic toxicity. In human liver tissues, Cadd4 effectively degraded PCSK9 and restored LDLR expression. Compared with the clinical-stage PCSK9 inhibitor AZD0780, Cadd4 demonstrated superior lipid-lowering efficacy and a longer duration of action. CONCLUSION: Cadd4 represents a promising CADD-designed therapeutic strategy for cholesterol management by targeting intracellular PCSK9 for degradation. This approach overcomes key limitations of existing therapies and underscores the potential of targeted protein degradation in cardiovascular disease treatment.